Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus (QoL)

Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus - A Multi-center Evaluation of Health-related Quality of Life Assessments and Biomarkers of Exposure and Harm

To evaluate selected biomarkers of tobacco exposure and biomarkers of harm and assess quality of life measures in smokers randomly switched from their usual brand of cigarette to one of three test products: (1) a tobacco-heating cigarette; (2) snus (smokeless tobacco); or (3) an ultra-low machine yield tobacco-burning cigarette.

Study Overview

• Status: Completed
• Conditions: Cigarette Smoking
• Intervention / Treatment: Other: Tobacco-Heating Cigarette; Other: Snus (Smokeless Tobacco); Other: Tobacco-Burning Cigarette

Detailed Description

A randomized, multi-center, 4-group study of health status measures and biomarkers in subjects who smoke and are switched to either a tobacco-heating cigarette, snus, or a tobacco-burning cigarette, with a non-treatment group of never-smokers.

Primary Objectives:

• Evaluate select biomarkers of tobacco exposure and biomarkers of harm from subjects who smoke and who are switched to a tobacco-heating cigarette, snus, or a tobacco-burning cigarette.
• Evaluate ability of a tobacco-heating cigarette and snus to modify patient-reported Chronic Obstructive Pulmonary Disease (COPD)-related health status in subjects who smoke and are switched to either a tobacco-heating cigarette or snus relative to a control group (a tobacco-burning ultra-low machine yield [ULMY]) cigarette.
• Assess subject compliance.

Secondary Objectives:

• Measure amount and repeatability of smoke components yielded from the cigarettes (yield in use) and determine relative uptake of selected smoke components.
• Evaluate the ability of a tobacco-heating cigarette and snus to modify general health status as measured by self-administered health questionnaires in subjects who smoke and are switched to either a tobacco-heating cigarette or snus relative to a control group (a tobacco-burning ULMY cigarette).
• Compare health status measures in smokers who are switched to a tobacco-heating cigarette to smokers who are switched to snus.
• Compare baseline data from all tobacco-using groups to baseline data from the never-smoking (non-treatment) group.

• Study Type: Interventional
• Enrollment (Actual): 163
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Daytona, Florida, United States, 32117
      • Covance Clinical Research Unit, Inc.
  • Idaho
    • Boise, Idaho, United States, 83704
      • Covance Clinical Research Unit, Inc.
  • Oregon
    • Portland, Oregon, United States, 97239
      • Covance Clinical Research Unit, Inc.
  • Texas
    • Austin, Texas, United States, 78752
      • Covance Clinical Research Unit, Inc.
    • Dallas, Texas, United States, 75247
      • Covance Clinical Research Unit, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 28 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or females, between 28 and 55 years of age, inclusive.
• Cigarette-only smokers who currently smoked at least 15 cigarettes daily and who smoked for at least 10 years prior to Week 0 (i.e., chronic cigarette smokers).
• Smokers not intending to quit smoking, but willing to switch their tobacco product (intent to quit was defined as intending to make or making a quit attempt within 1 month prior to Week 0).
• Non-smoking subjects who self-reported "Never-Smoker" per the American Thoracic Society Questionnaire definition, and did not have urinary cotinine levels exceeding 50 ng/mL.
• Subjects, in the opinion of the Investigators, free of clinically significant health problems and not on medication on a daily basis for chronic medical disorders deemed clinically significant by the Investigator(s).
• Subjects not regularly taking creatine supplements.
• Subjects testing negative for selected drugs of abuse at Screening (included alcohol test).
• Subjects with a negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]) and negative Human Immunodeficiency Virus (HIV) antibody screens (for subjects immunized against hepatitis B with documentation of this immunization, a positive test result was not exclusionary).
• Female subjects who were non-pregnant (urine pregnancy test results were negative at Screening and Weeks 0, 12, and 24), non-lactating, and either postmenopausal (as verified by Follicle Stimulating Hormone levels) for at least 1 year, surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days, or agreed to use from the time of signing the informed consent until 30 days after Week 24 (or Study Completion) a form of contraception considered acceptable to the Investigators (such as oral, injectable or implantable contraceptives, intrauterine devices and barrier methods ).
• Subjects able to read and comprehend questionnaires in English and willing to sign an Informed Consent Form.

Exclusion Criteria:

• Smokers using any other tobacco or nicotine-containing product or device other than tobacco-burning cigarettes from 6 months prior to the study through Week 24, including cigars, pipes, chewing tobacco, snuff, snus, nicotine patch, nicotine gum, etc.
• A history or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders.
• A history of hypersensitivity or allergies to any drug compound unless approved by the Investigator(s).
• A history or presence of an abnormal ECG deemed clinically significant by the Investigator.
• A history of alcoholism or drug addiction within 1 year prior to Study Entry.
• Evidence of visible oral cancer, as found in an oral health examination or based on oral health questions at each visit.
• Any acute or chronic condition that, in the Investigator(s)' opinion, limited the subject's ability to complete and/or participate in the study.
• Donation of blood from 30 days prior to Screening through Week 24 (or Study Completion), inclusive, or plasma from 2 weeks prior to Screening through Week 24 (or Study Completion), inclusive.
• Receipt of blood products within 2 months prior to Study Entry.
• Subject or a relative of the subject was currently or had ever been employed by the tobacco industry.
• Subject participated in any other investigational study drug or product trial in which receipt of an investigational study drug or product occurred within 30 days prior to Check-in (inclusive).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tobacco-Heating Cigarette; A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette	Other: Tobacco-Heating Cigarette; Smokers switched to a tobacco-heating cigarette for 24 weeks
Experimental: Snus (Smokeless Tobacco); A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)	Other: Snus (Smokeless Tobacco); Smokers switched to snus product for 24 weeks
Experimental: Tobacco-Burning Cigarette; A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette	Other: Tobacco-Burning Cigarette; Smokers switched to a tobacco-burning cigarette for 24 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Urinary Tobacco Exposure Biomarkers from Weeks 0 to 12	Nicotine and nine metabolites, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, aromatic amines, benzene, isoprostanes, and urine mutagenicity	Week 12
Change in Blood Tobacco Exposure Biomarkers from Weeks 0 to 12	Lipid/cardiac risk markers, hypercoagulable state markers, endothelial function, DNA damage, and carboxyhemoglobin	Week 12
Change in Markers of Exposure and Potential Harm from Weeks 0 to 12	Exhaled carbon monoxide and spirometry	Week 12
Change in health status scores from self-administered questionnaires on COPD-related disease from Weeks 0 to 12	St. George's Respiratory Questionnaire and Leicester Cough Questionnaire	Week 12
Change in tobacco usage diary from Weeks 0 to 4		Week 4
Change in Urinary Tobacco Exposure Biomarkers from Weeks 0 to 24	Nicotine and nine metabolites, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, aromatic amines, benzene, isoprostanes, and urine mutagenicity	Week 24
Change in Blood Tobacco Exposure Biomarkers from Weeks 0 to 24	Lipid/cardiac risk markers, hypercoagulable state markers, endothelial function, DNA damage, and carboxyhemoglobin	Week 24
Change in Markers of Exposure and Potential Harm from Weeks 0 to 24	Exhaled carbon monoxide and spirometry	Week 24
Change in daily tobacco usage diary from Weeks 4 to 8		Week 8
Change in daily tobacco usage diary from Weeks 8 to 12		Week 12
Change in daily tobacco usage diary from Weeks 12 to 16		Week 16
Change in daily tobacco usage diary from Weeks 16 to 20		Week 20
Change in daily tobacco usage diary from Weeks 20 to 24		Week 24
Change in health status scores from self-administered questionnaires on COPD-related disease from Weeks 0 to 24	St. George's Respiratory Questionnaire and Leicester Cough Questionnaire	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Nicotine Yield versus Uptake from Weeks 0 to 12	Mouth-level exposure to tar and nicotine	Week 12
Change in health status scores from self-administered questionnaires on general health from Weeks 0 to 12	Smoking Cessation Quality of Life Questionnaire (inclusive of the SF-36 v2)	Week 12
Change in Nicotine Yield versus Uptake from Weeks 0 to 24	Mouth-level exposure to tar and nicotine	Week 24
Change in health status scores from self-administered questionnaires on general health from Weeks 0 to 24	Smoking Cessation Quality of Life Questionnaire (inclusive of the SF-36 v2)	Week 24

Collaborators and Investigators

• Sponsor: R.J. Reynolds Tobacco Company
• Collaborators: University of Louisville; Covance; Analytisch-biologisches Forschungslabor GmbH; Arista Laboratories; Covance IVRS; Pacific Biomarkers
• Investigators: Principal Investigator: Michael W Ogden, Ph.D., R.J. Reynolds Tobacco Company

Publications and helpful links

General Publications

• Ogden MW, Marano KM, Jones BA, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 1. Study design and methodology. Biomarkers. 2015;20(6-7):382-90. doi: 10.3109/1354750X.2015.1094133. Epub 2015 Nov 2.
• Ogden MW, Marano KM, Jones BA, Morgan WT, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 2. Biomarkers of exposure. Biomarkers. 2015;20(6-7):391-403. doi: 10.3109/1354750X.2015.1094134. Epub 2015 Nov 10.
• Ogden MW, Marano KM, Jones BA, Morgan WT, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effect. Biomarkers. 2015;20(6-7):404-10. doi: 10.3109/1354750X.2015.1094135. Epub 2015 Nov 2.

Study record dates

Study Major Dates

• Study Start: February 1, 2007
• Primary Completion (Actual): November 1, 2007
• Study Completion (Actual): November 1, 2009

Study Registration Dates

• First Submitted: February 5, 2014
• First Submitted That Met QC Criteria: February 11, 2014
• First Posted (Estimate): February 13, 2014

Study Record Updates

• Last Update Posted (Estimate): February 17, 2016
• Last Update Submitted That Met QC Criteria: February 15, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Quality of Life; Smoking; Tobacco; Biomarkers; Exposure; Tobacco-heating; Smokeless Tobacco; Snus
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Respiratory System Agents; Lobeline
• Other Study ID Numbers: HSD-0702

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No